Treatment of hepatitis B virus-infected patients: utility of therapeutic recommendations in developing countries

Bibliography

• Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004;350:1118-29
   PubMed Web of Science ®Google Scholar
• Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-45
   PubMed Web of Science ®Google Scholar
• Lok AS. Chronic hepatitis B. N Engl J Med 2002;346:1682-3
   PubMed Web of Science ®Google Scholar
• Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis 2003;23:47-58
   PubMed Web of Science ®Google Scholar
• Lok AS. The maze of treatments for hepatitis B. N Engl J Med 2005;352:2743-6
   PubMed Web of Science ®Google Scholar
• Singh NA, Reau N. Management of hepatitis B virus. J Antimicrob Chemother 2008;62:224-8
   PubMed Web of Science ®Google Scholar
• Ferir G, Kaptein S, Neyts J, et al. Antiviral treatment of chronic hepatitis B virus infections; the past, the present and the future. Rev Med Virol 2008;18:19-34
   PubMed Web of Science ®Google Scholar
• Fung J, Lai CL, Yuen MF. New paradigms for the treatment of chronic hepatitis B. J Gastroenterol Hepatol 2008;23:1182-92
   PubMed Web of Science ®Google Scholar
• Karayiannis P. Hepatitis B virus: old, new and future approaches to antiviral treatment. J Antimicrob Chemother 2003;51:761-85
   PubMed Web of Science ®Google Scholar
• Craxi A, Antonucci G, Camma C. Ttreament options in HBV. J Hepatol 2006;44:S77-83
   Web of Science ®Google Scholar
• Mahoney FJ. Update of diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev 1999;12:351-66
   PubMed Web of Science ®Google Scholar
• Jung MC, Pape GR. Immunology of hepatitis B infection. Lancet Infect Dis 2002;2:43-50
   PubMed Web of Science ®Google Scholar
• Pungparong S, Kim WR, Poterucha JJ. Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin Proc 2007;82:967-75
   PubMed Web of Science ®Google Scholar
• Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000: summary of a workshop. Gastroenterology 2001;120:1828-53
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL clinical practice guidelines; Management of chronic hepatitis B. J Hepatol 2009;50:227-42
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-39
   PubMed Web of Science ®Google Scholar
• Chang JJ, Lewin SR. Immunopathogenesis of hepatitis B virus infection. Immunol Cell Biol 2007;85:16-23
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM, Dusheiko G, Hatzakis A, et al. Virological monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 2008;134:405-15
   PubMed Web of Science ®Google Scholar
• Perrillo RP, Gish RG, Peters M, et al. Chronic hepatitis B: a critical appraisal of current approaches to therapy. Clin Gastroenterol Hepatol 2006;4:233-48
   PubMed Web of Science ®Google Scholar
• Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008;22:262-83
   Google Scholar
• Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008;6:1315-41
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis 2006;26:130-41
   PubMed Web of Science ®Google Scholar
• Viola L, Harrison I, Coleman J, et al. Natural history of liver disease in chronic hepatitis B surface antigen carriers: survey of 100 patients from Great Britain. Lancet 1981;ii:1156-9
   Google Scholar
• Liaw Y, Chu C, Su I, et al. Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology 1983;84:216-9
   PubMed Web of Science ®Google Scholar
• Fattovich G, Rugge M, Brollo L, et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986;6:167-72
   PubMed Web of Science ®Google Scholar
• Bertoletti A, Maini MK. Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection? Curr Opin Immunol 2000;12:403-8
   PubMed Web of Science ®Google Scholar
• Perrillo RP. Therapy of hepatitis B -viral suppression or eradication? Hepatology 2006;43:S182-93
   PubMed Web of Science ®Google Scholar
• Papatheodoridis GV, Hadziyannis SJ. Current management of chronic hepatitis B. Aliment Pharmacol Ther 2004;19:25-37
   PubMed Web of Science ®Google Scholar
• Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006;43:S173-81
   PubMed Web of Science ®Google Scholar
• Hadziyannis S. Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepat Rev 1995;1:7-36
   Google Scholar
• Liu CJ, Kao JH, Chen DS. Therapeutic implications of hepatitis B virus genotypes. Liv Int 2005;25:1097-107
   PubMed Web of Science ®Google Scholar
• Iser DM, Sasadeusz JJ. Current treatment of HIV/hepatitis B virus coinfection. J Gastroenterol Hepatol 2008;23:699-706
   PubMed Web of Science ®Google Scholar
• Wong DK, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A metaanalysis. Ann Intern Med 1993;119:312-23
   PubMed Web of Science ®Google Scholar
• Perillo R, Schiff E, Davis G, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990;323:295-301
   PubMed Web of Science ®Google Scholar
• Korenman J, Baker B, Waggoner J, et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991;114:629-34
   PubMed Web of Science ®Google Scholar
• Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123-9
   PubMed Web of Science ®Google Scholar
• Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-95
   PubMed Web of Science ®Google Scholar
• Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206-17
   PubMed Web of Science ®Google Scholar
• Cooksley WG, Piratvisuth T, Lee SD, et al. Pegylated alpha-2a (40KDa): an evidence in the treatment of hepatitis B e antigen-positive chronic hepatitis. J Viral Hepat 2003;36:298-305
   Google Scholar
• Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31
   PubMed Web of Science ®Google Scholar
• Buti M, Cotrina M, Jardi R, et al. Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B. J Viral Hepat 2001;8:270-5
   PubMed Web of Science ®Google Scholar
• de Franchis R, Hadengue A, Lau G, et al. ASL International Consensus Conference on Hepatitis B, Consensus statement (long version), 13–14 September, 2002 Geneva, Switzerland. J Hepatol 2003;39(Suppl 1):S3-25
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63
   PubMed Web of Science ®Google Scholar
• Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B and antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-7
   PubMed Web of Science ®Google Scholar
• Wolters LM, Hansen BE, Niesters HG, et al. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J Hepatol 2002;37:137-44
   PubMed Web of Science ®Google Scholar
• Lai CL, Leung N, Tei EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen positive chronic hepatitis B. Gastroenterology 2005;129:526-36
   Google Scholar
• Lai C-L, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-88
   PubMed Web of Science ®Google Scholar
• Marcellin P, Heathcote J, Buti M, et al. Tenofovir disoproxil versus adefovir dipivoxil for chronic hepatitis B. N Eng J Med 2008;359:2442-55
   PubMed Web of Science ®Google Scholar
• van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004;40:1421-5
   PubMed Web of Science ®Google Scholar
• Gish RG, Trinh H, Leung N, et al. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. J Hepatol 2005;43:60-6
   PubMed Web of Science ®Google Scholar
• Fung SK, Wong F, Hussain M, et al. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepatol 2004;11:432-8
   PubMed Web of Science ®Google Scholar
• Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-20
   PubMed Web of Science ®Google Scholar
• Zoulim F. Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance? Antivir Chem Chemother 2004;15:299-305
   PubMedGoogle Scholar
• Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic Hepatitis B virus infection. Antiviral Res 2004;64:1-5
   PubMed Web of Science ®Google Scholar
• Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003;36:687-96
   PubMed Web of Science ®Google Scholar
• Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-22
   PubMed Web of Science ®Google Scholar
• Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003;125:292-7
   PubMed Web of Science ®Google Scholar
• Brunelle MN, Jacquard AC, Pichoud C, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005;41:1391-8
   PubMed Web of Science ®Google Scholar
• Villet S, Billioud G, Pichoud C, et al. In vitro characterization of viral fitness of therapy-resistant hepatitis B variants. Gastroenterology 2009;136:168-76
   PubMed Web of Science ®Google Scholar
• Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006;44:1656-65
   PubMed Web of Science ®Google Scholar
• Delaney WE 4th, Borroto-Esoda K. Therapy of chronic hepatitis B: trends and developments. Curr Opin Pharmacol 2008;8:532-40
   PubMed Web of Science ®Google Scholar
• Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for the treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006;130:2039-49
   PubMed Web of Science ®Google Scholar
• Tenney DJ, Rose RE, Baldick CJ, et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007;51:902-11
   PubMed Web of Science ®Google Scholar
• Baldick CJ, Eggers BJ, Fang J, et al. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response. J Hepatol 2008;48:895-902
   PubMed Web of Science ®Google Scholar
• Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004;48:3498-507
   PubMed Web of Science ®Google Scholar
• Kumar M, Sarin SK. Systemic review: combination therapies for treatment-naïve chronic hepatitis B. Aliment Pharmacol Ther 2008;27:1187-209
   PubMed Web of Science ®Google Scholar
• Schalm SW, Heathcote J, Ciancira J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomized-controlled trial. Gut 2000;46:562-8
   PubMed Web of Science ®Google Scholar
• Hilleman MR. Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus. Vaccine 2003;21:4626-49
   PubMed Web of Science ®Google Scholar
• Pol S. Immunotherapy of chronic hepatitis B by anti HBV vaccine. Biomed Pharmacother 1995;49:105-9
   PubMed Web of Science ®Google Scholar
• Sprengers D, Janssen HL, Kwekkeboom J, et al. In vivo immunization following virus suppression: a novel approach for inducing immune control in chronic hepatitis B. J Viral Hepatol 2003;10:7-9
   PubMed Web of Science ®Google Scholar
• Akbar SM, Furukawa S, Horiike N, et al. Vaccine therapy for hepatitis B virus carrier. Curr Drug Targets Infect Disord 2004;4:93-101
   PubMedGoogle Scholar
• Horiike N, Akbar SM, Michitaka K, et al. In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. J Clin Virol 2005;32:156-61
   PubMed Web of Science ®Google Scholar
• Sprengers D, Janssen HL. Immunomodulatory therapy for chronic hepatitis B virus infection. Fundam Clin Pharmacol 2005;19:17-26
   PubMed Web of Science ®Google Scholar
• Shamiliyan TA, MacDonald R, Shaukat A, et al. Antiviral therapy for adults with chronic hepatitis B; A systemic review for a national institute of health consensus development conference. Ann Intern Med 2009;150:111-24
   PubMed Web of Science ®Google Scholar
• Artan R. Lamivudine monotherapy in children with immune-tolerant chronic hepatitis B. J Chemother 2005;17:198-202
   PubMed Web of Science ®Google Scholar
• Hirsch MS, Gunthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an international AIDS society-USA panel. Curr Infect Dis 2008;47:266-85
   Google Scholar